StockFame
  • Trending News
  • Markets
  • US Markets
  • Indian Stocks
  • Economics
  • Crypto News
Select Page

Zydus plans obesity jab launch in a novel pen device

by Live mint | February 25, 2026 10:05 pm | Indian Stocks, Market, News

Zydus has received regulatory approval from the Drug Controller General of India (DCGI) to market and manufacture semaglutide to treat type 2 diabetes and obesity.

Recent Posts

  • Hut 8 swings to Q4 loss; compute revenue contribution increases
  • MrBeast editor nabbed by prediction market firm Kalshi for alleged insider trading
  • Samsung’s S26 gives an advance look at what the Google-powered Apple Siri could do
  • Thrive Capital invested about $1 billion in OpenAI at a $285 billion valuation, source says
  • Big Tech companies to meet Trump at White House to sign pledge on data center power costs

About Stockfame

Stockfame is a global media platform delivering bold insights on business, markets, technology, leadership, and entrepreneurship. We bring you research-backed news and sharp analysis to help you stay ahead of the curve.

Quick News Links

  • Crypto News
  • Indian Stocks
  • Latest Posts
  • Market
  • News
  • Trending News
  • US Markets

Contact Us

Reach out to us at:
Phone:  [+91] 9834938257
Email: contact@stockfame.com
For Advertisement, Press Releases, Partnerships or to get backlinks on this website, please e-mail us at contact@stockfame.com

Quick Reads

  • Global market news
  • Crypto Market News
  • Indian Market News
  • Economy News
  • Latest Business News
  • About
  • Terms and Conditions
  • Privacy Policy
  • Website User Agreement
  • Disclaimer
  • Facebook
  • X
  • Instagram
  • RSS
Copyright @StockFame | All Rights Reserved